Fig. 8From: Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case reportSummary of the clinical course of the present case. RCC renal cell carcinoma, Ipi ipilimumab, Nivo nivolumab, irAEs immune-related adverse eventsBack to article page